Cargando…

Development of preclinical and clinical models for immune-related adverse events following checkpoint immunotherapy: a perspective from SITC and AACR

Recent advances in cancer immunotherapy have completely revolutionized cancer treatment strategies. Nonetheless, the increasing incidence of immune-related adverse events (irAEs) is now limiting the overall benefits of these treatments. irAEs are well-recognized side effects of some of the most effe...

Descripción completa

Detalles Bibliográficos
Autores principales: Bayless, Nicholas L, Bluestone, Jeffrey A, Bucktrout, Samantha, Butterfield, Lisa H, Jaffee, Elizabeth M, Koch, Christian A, Roep, Bart O, Sharpe, Arlene H, Murphy, William J, Villani, Alexandra-Chloé, Walunas, Theresa L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8420733/
https://www.ncbi.nlm.nih.gov/pubmed/34479924
http://dx.doi.org/10.1136/jitc-2021-002627
_version_ 1783748937748840448
author Bayless, Nicholas L
Bluestone, Jeffrey A
Bucktrout, Samantha
Butterfield, Lisa H
Jaffee, Elizabeth M
Koch, Christian A
Roep, Bart O
Sharpe, Arlene H
Murphy, William J
Villani, Alexandra-Chloé
Walunas, Theresa L
author_facet Bayless, Nicholas L
Bluestone, Jeffrey A
Bucktrout, Samantha
Butterfield, Lisa H
Jaffee, Elizabeth M
Koch, Christian A
Roep, Bart O
Sharpe, Arlene H
Murphy, William J
Villani, Alexandra-Chloé
Walunas, Theresa L
author_sort Bayless, Nicholas L
collection PubMed
description Recent advances in cancer immunotherapy have completely revolutionized cancer treatment strategies. Nonetheless, the increasing incidence of immune-related adverse events (irAEs) is now limiting the overall benefits of these treatments. irAEs are well-recognized side effects of some of the most effective cancer immunotherapy agents, including antibody blockade of the cytotoxic T-lymphocyte-associated protein 4 and programmed death protein 1/programmed-death ligand 1 pathways. To develop an action plan on the key elements needed to unravel and understand the key mechanisms driving irAEs, the Society for Immunotherapy for Cancer and the American Association for Cancer Research partnered to bring together research and clinical experts in cancer immunotherapy, autoimmunity, immune regulation, genetics and informatics who are investigating irAEs using animal models, clinical data and patient specimens to discuss current strategies and identify the critical next steps needed to create breakthroughs in our understanding of these toxicities. The genetic and environmental risk factors, immune cell subsets and other key immunological mediators and the unique clinical presentations of irAEs across the different organ systems were the foundation for identifying key opportunities and future directions described in this report. These include the pressing need for significantly improved preclinical model systems, broader collection of biospecimens with standardized collection and clinical annotation made available for research and integration of electronic health record and multiomic data with harmonized and standardized methods, definitions and terminologies to further our understanding of irAE pathogenesis. Based on these needs, this report makes a set of recommendations to advance our understanding of irAE mechanisms, which will be crucial to prevent their occurrence and improve their treatment.
format Online
Article
Text
id pubmed-8420733
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-84207332021-09-22 Development of preclinical and clinical models for immune-related adverse events following checkpoint immunotherapy: a perspective from SITC and AACR Bayless, Nicholas L Bluestone, Jeffrey A Bucktrout, Samantha Butterfield, Lisa H Jaffee, Elizabeth M Koch, Christian A Roep, Bart O Sharpe, Arlene H Murphy, William J Villani, Alexandra-Chloé Walunas, Theresa L J Immunother Cancer Review Recent advances in cancer immunotherapy have completely revolutionized cancer treatment strategies. Nonetheless, the increasing incidence of immune-related adverse events (irAEs) is now limiting the overall benefits of these treatments. irAEs are well-recognized side effects of some of the most effective cancer immunotherapy agents, including antibody blockade of the cytotoxic T-lymphocyte-associated protein 4 and programmed death protein 1/programmed-death ligand 1 pathways. To develop an action plan on the key elements needed to unravel and understand the key mechanisms driving irAEs, the Society for Immunotherapy for Cancer and the American Association for Cancer Research partnered to bring together research and clinical experts in cancer immunotherapy, autoimmunity, immune regulation, genetics and informatics who are investigating irAEs using animal models, clinical data and patient specimens to discuss current strategies and identify the critical next steps needed to create breakthroughs in our understanding of these toxicities. The genetic and environmental risk factors, immune cell subsets and other key immunological mediators and the unique clinical presentations of irAEs across the different organ systems were the foundation for identifying key opportunities and future directions described in this report. These include the pressing need for significantly improved preclinical model systems, broader collection of biospecimens with standardized collection and clinical annotation made available for research and integration of electronic health record and multiomic data with harmonized and standardized methods, definitions and terminologies to further our understanding of irAE pathogenesis. Based on these needs, this report makes a set of recommendations to advance our understanding of irAE mechanisms, which will be crucial to prevent their occurrence and improve their treatment. BMJ Publishing Group 2021-09-03 /pmc/articles/PMC8420733/ /pubmed/34479924 http://dx.doi.org/10.1136/jitc-2021-002627 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Review
Bayless, Nicholas L
Bluestone, Jeffrey A
Bucktrout, Samantha
Butterfield, Lisa H
Jaffee, Elizabeth M
Koch, Christian A
Roep, Bart O
Sharpe, Arlene H
Murphy, William J
Villani, Alexandra-Chloé
Walunas, Theresa L
Development of preclinical and clinical models for immune-related adverse events following checkpoint immunotherapy: a perspective from SITC and AACR
title Development of preclinical and clinical models for immune-related adverse events following checkpoint immunotherapy: a perspective from SITC and AACR
title_full Development of preclinical and clinical models for immune-related adverse events following checkpoint immunotherapy: a perspective from SITC and AACR
title_fullStr Development of preclinical and clinical models for immune-related adverse events following checkpoint immunotherapy: a perspective from SITC and AACR
title_full_unstemmed Development of preclinical and clinical models for immune-related adverse events following checkpoint immunotherapy: a perspective from SITC and AACR
title_short Development of preclinical and clinical models for immune-related adverse events following checkpoint immunotherapy: a perspective from SITC and AACR
title_sort development of preclinical and clinical models for immune-related adverse events following checkpoint immunotherapy: a perspective from sitc and aacr
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8420733/
https://www.ncbi.nlm.nih.gov/pubmed/34479924
http://dx.doi.org/10.1136/jitc-2021-002627
work_keys_str_mv AT baylessnicholasl developmentofpreclinicalandclinicalmodelsforimmunerelatedadverseeventsfollowingcheckpointimmunotherapyaperspectivefromsitcandaacr
AT bluestonejeffreya developmentofpreclinicalandclinicalmodelsforimmunerelatedadverseeventsfollowingcheckpointimmunotherapyaperspectivefromsitcandaacr
AT bucktroutsamantha developmentofpreclinicalandclinicalmodelsforimmunerelatedadverseeventsfollowingcheckpointimmunotherapyaperspectivefromsitcandaacr
AT butterfieldlisah developmentofpreclinicalandclinicalmodelsforimmunerelatedadverseeventsfollowingcheckpointimmunotherapyaperspectivefromsitcandaacr
AT jaffeeelizabethm developmentofpreclinicalandclinicalmodelsforimmunerelatedadverseeventsfollowingcheckpointimmunotherapyaperspectivefromsitcandaacr
AT kochchristiana developmentofpreclinicalandclinicalmodelsforimmunerelatedadverseeventsfollowingcheckpointimmunotherapyaperspectivefromsitcandaacr
AT roepbarto developmentofpreclinicalandclinicalmodelsforimmunerelatedadverseeventsfollowingcheckpointimmunotherapyaperspectivefromsitcandaacr
AT sharpearleneh developmentofpreclinicalandclinicalmodelsforimmunerelatedadverseeventsfollowingcheckpointimmunotherapyaperspectivefromsitcandaacr
AT murphywilliamj developmentofpreclinicalandclinicalmodelsforimmunerelatedadverseeventsfollowingcheckpointimmunotherapyaperspectivefromsitcandaacr
AT villanialexandrachloe developmentofpreclinicalandclinicalmodelsforimmunerelatedadverseeventsfollowingcheckpointimmunotherapyaperspectivefromsitcandaacr
AT walunastheresal developmentofpreclinicalandclinicalmodelsforimmunerelatedadverseeventsfollowingcheckpointimmunotherapyaperspectivefromsitcandaacr